CTSD and metabolic dysfunction-associated steatotic liver disease: As a result of excess lipids, extracellular CTSD secretion is elevated, where its increased activity in the plasma is known to be associated with metabolic inflammatory disorders such as NAFLD (16), atherosclerosis (17) and type 2 diabetes (18).